Stock Rich List
#261 on the corporate holders of 813 holders

Nant Capital, LLC

10% owner at ImmunityBio; 10% owner at PDS Biotechnology.

$562M
in disclosed stock, −$10.6M (−1.85%) today
Market closed. Prices as of Nov 19, 4:04 PM ET
Rank
261st of 813
Companies held
2
Largest holding
IBRX, 98.1% of total
Latest SEC filing
Sep 14, 2026
Listed but not counted
$3.38B

What the $562M is made of

Holdings counted

All filings on SEC.gov
CompanyHow heldSharesPriceValueShare of totalReported
ImmunityBio IBRX
Common Stock
Directly29,701,752$6.57$195M34.7%Form 4, Feb 10, 2026
ImmunityBio IBRX
Common Stock
Through NantMobile, LLC
Reported jointly by 2 insiders; split evenly
23,778,967$6.57$156M27.8%Form 4, Feb 10, 2026
ImmunityBio IBRX
Common Stock
Through NantCancerStemCell, LLC
Reported jointly by 2 insiders; split evenly
16,303,493$6.57$107M19.1%Form 4, Feb 10, 2026
ImmunityBio IBRX
Common Stock
Through California Capital Equity, LLC7,976,159$6.57$52.4M9.3%Form 4, Feb 10, 2026
ImmunityBio IBRX
Common Stock
Indirectly (see filing footnote)
Reported jointly by 3 insiders; split evenly
3,328,973$6.57$21.9M3.9%Form 4, Feb 10, 2026
ImmunityBio IBRX
Common Stock
Through NantBio, Inc.
Reported jointly by 3 insiders; split evenly
2,794,471$6.57$18.4M3.3%Form 4, Feb 10, 2026
PDS Biotechnology PDSB
Common Stock
Indirectly (see filing footnote)13,005,334$0.81$10.5M1.9%Form 3, Sep 14, 2026

Share counts are the amounts Nant Capital, LLC reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.

Reported but not counted

These shares appear on Nant Capital, LLC's filings but are held for charities, by investment funds the insider manages, or could not be valued reliably. Insiders usually disclaim ownership of fund holdings beyond their personal stake.

CompanyHow heldSharesPriceValueShare of totalReported
ImmunityBio IBRX
Common Stock
Through Cambridge Equities, LP
Held by a company or fund the insider manages
261,705,814$6.57$1.72B—Form 4, Feb 10, 2026
ImmunityBio IBRX
Common Stock
Through Nant Capital, LLC
Held by an investment fund or partnership
246,412,277$6.57$1.62B—Form 4, Feb 10, 2026
ImmunityBio IBRX
Common Stock
Through Chan Soon-Shiong Family Foundation
Held for a foundation or charity
5,618,326$6.57$36.9M—Form 4, Feb 10, 2026

Nearby on the list

Full list
Nearby ranks
RankNameStock holdingsToday
258Trv GP Iv, LLC
10% owner, Tango Therapeutics
$563M+$13.6M (+2.47%)
259PC Connection INC
10% owner, PC Connection
$563M−$7.0M (−1.23%)
2603MR Partners, L.P.
10% owner, Rush Enterprises
$563M−$37.3M (−6.21%)
261Nant Capital, LLC
10% owner, ImmunityBio
$562M−$10.6M (−1.85%)
262Summit Investors GE Ix/vc IV (uk), L.P.
10% owner, Klaviyo
$559M−$18.0M (−3.12%)
263Apollo Capital Management VIII, LLC
10% owner, Hilton Grand Vacations
$558M−$22.5M (−3.88%)
264ICONIQ Strategic Partners IV, L.P.
10% owner, Procore Technologies
$557M−$19.8M (−3.44%)

Other ImmunityBio insiders

All IBRX insiders

Questions

How much stock does Nant Capital, LLC own?

Nant Capital, LLC holds $561,615,872 in listed stock based on SEC filings and current prices, mostly ImmunityBio (IBRX). That ranks 261st on the Stock Rich List.

Is this Nant Capital, LLC's net worth?

No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.

Files jointly with SEC filer 1189020.